Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies.
Uta KiltzJames Cheng-Chung WeiDésirée Mfm van der HeijdeFilip E Van den BoschJessica A WalshAnnelies BoonenLianne S GenslerTheresa HunterHilde CarlierYan DongXiaoqi LiRebecca BolceVibeke StrandJüergen BraunPublished in: The Journal of rheumatology (2020)
IXE significantly improved functioning and health as assessed by both generic and disease-specific measures, as well as societal health utility values in patients with r-axSpA, as measured by SF-36, ASAS HI, and EQ-5D-5L at Week 16, and improvements were sustained through 52 weeks.